About EOCI

EOCI has a demonstrated track record of over 18 years in the CME industry. Our reputation is a result of business integrity and professional agility, as well as resourcefulness and creativity.

In addition to the 50-100 CME programs we develop annually, EOCI produces other high-calibre specialist-focused annual congresses across Canada.

VIRTUAL EXHIBIT HALL

Overall Conference Learning Objectives

By the end of this event, participants will be able to:

  • Discuss evolving concepts in the management of heart failure, dyslipidemia, vascular disease, and cardiac amyloidosis
  • Examine the results and practical implications of the latest clinical trial results in cardiovascular medicine
  • Evaluate the optimal integration of contemporary and emerging cardiovascular therapeutics into clinical practice
  • Review and debate approaches to the management of complex cardiovascular patient presentations

Session Learning Objectives

Plenary Session Day 1: Friday, June 12, 2020

A New Age for Heart Failure Therapy

Shelley Zieroth, MD

Following this session, participants will be able to:

  • Explore contemporary and emerging approaches to the management of heart failure

Antithrombotics after ACS for AF patients

Atul Verma, MD

Following this session, participants will be able to:

  • Discuss the efficacy and safety of dual vs triple antithrombotic regimens in AF patients with ACS

ABCD’s of ATTR Amyloidosis

Katie Connolly, MD

Following this session, participants will be able to:

  • Review the disease spectrum of TTR amyloidosis and the evolving treatment landscape

SGLT2i Mechanisms

Jacob A. Udell, MD

Following this session, participants will be able to:

  • Examine the pleiotropic effects of SGLT2i inhibitors and their potential impact across different cardio-metabolic diseases

How an Electrician Can Help Manage Heart Failure

Atul Verma, MD

Following this session, participants will be able to:

  • Provide a rationale for choosing between CRT-D versus CRT-P therapy

Saving Life and Limb: Anti-thrombotic Therapy for Vascular Disease

Patrice Nault, MD

Following this session, participants will be able to:

  • Determine the risk of adverse CV/ limb events and guideline-recommended treatment options

2020 Update on Lipid Management: Beyond Statins

Jean Grégoire, MD

Following this session, participants will be able to:

  • Review the evidence and guideline recommendations for the use of non-statin therapies for dyslipidemia

Friday Workshops

Workshop A - How to Keep Calm and Treat NOAC-Associated Bleeding?

Deborah Siegal, MD

Following this session, participants will be able to:

  • Discuss a systematic approach to assessing and treating minor, moderate and severe bleeding events in patients receiving NOACs

Workshop B - Cardiac Amyloidosis: Have I missed it? How do I treat it?

Katie Connolly, MD

Following this session, participants will be able to:

  • Review the key signs and symptoms cardiac amyloidosis and the application of current and emerging treatment options

Workshop A - The Genetics of Heart Failure: What Clinicians Should Know

Jeff Healey, MD

Following this session, participants will be able to:

  • Describe the main genetic causes of inherited heart muscle disease and insights provided by candidate gene and genome-wide association studies

Workshop B - New Tools to Fix Hearts

Shamir Mehta, MD

Following this session, participants will be able to:

  • Highlight the current and future state of devices for the management of cardiac disease

Plenary Session Day 2: Saturday, June 13, 2020

CV Prevention with Diabetes Drugs – the RCT Evidence

Hertzel Gerstein, MD

Following this session, participants will be able to:

  • Review the evidence from CVOTs on the effectiveness of antidiabetic drugs for the primary and secondary prevention of CVD

COMPLETE and ISCHEMIA

Shamir Mehta, MD

Following this session, participants will be able to:

  • Examine recent evidence for revascularization of non-culprit lesions and in high-risk stable ischemic heart disease

Diet and CV Disease: Beyond the Hype

Mahshid Dehghan, MD

Following this session, participants will be able to:

  • Explore the links between diet and cardiovascular disease prevention and management

AF and Heart Failure? You Should See my Colleague

Jeff Healey, MD and Anique Ducharme, MD

Following this session, participants will be able to:

  • Debate the roles and responsibilities of the electrophysiologist and heart failure specialist, and discuss optimal strategies for co-management of complex cardiology patients

Inflammation and CVD: Understanding New Pathways

Jean-Claude Tardif, MD

Following this session, participants will be able to:

  • Discuss the evolving understanding of the inflammatory nature of CVD and implications for identifying new treatment targets

In-Patient and Out-Patient Management of HF: When is it the best time to optimize Tx?

Peter Liu, MD

Following this session, participants will be able to:

  • Discuss the practicalities of in-hospital vs out-patient initiation and optimization of HF therapies

The 20th Anniversary of HOPE: Looking Back at the Landmark Trial in Vascular Protection

Salim Yusuf, MD

Following this session, participants will be able to:

  • Provide a historical perspective on the evolution of definitions, goals and targets of vascular disease management

Saturday Workshops

Workshop A - Implantable and Wearable Monitors for Patients with Heart Failure & Afib

Kiran Sidhu, MD

Following this session, participants will be able to:

  • Understand the potential benefits and limitations of current and future innovations in implantable and wearable HF monitoring technologies

Workshop B - NOACs and Renally Impaired Patients: Green Light or Red Light?

Lena Rivard, MD

Following this session, participants will be able to:

  • Discuss the risks, benefits, and guideline recommendations of oral anticoagulation in patients with mild to severe renal impairment with a focus on NOACs

Workshop C - Using Machine Learning to Optimize Recruitment for Clinical Trials

Jeff Healey, MD

Following this session, participants will be able to:

  • Explore the current and future role of artificial intelligence in improving the efficiency of patient recruitment and optimizing cohort composition